Aducanumab was compared, in a blinded study, to three clinical-stage antibodies using chemical kinetics. The publication describes the use of chemical kinetic analysis to assess the mechanisms of action of four clinical stage anti-Aβ antibodies: aducanumab (Biogen), gantenerumab (Roche), bapineuzumab (Elan) and solanezumab (Eli Lilly). The results provide unique insights into potential correlations between suppression of specific molecular steps in the aggregation process and clinical outcomes. Of the four antibodies tested, only aducanumab dramatically reduces the flux of amyloid-β oligomers, a key neurotoxic species associated with AD.
Of Four Aβ Antibodies, Only Aducanumab Stems Tide of Toxic Oligomers
